A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jinf.2021.08.049
PubMed Identifier: 34606784
Publication URI: http://europepmc.org/abstract/MED/34606784
Type: Journal Article/Review
Volume: 84
Parent Publication: The Journal of infection
Issue: 1
ISSN: 0163-4453